Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 10, 2016

View Archived Issues

Pfenex announces positive phase Ia results for Px-563L anthrax vaccine

Charles River enters strategic partnership with Milner Therapeutics Institute and Consortium

Pfizer patents modulators of RORgamma t

Pfenex to regain full rights to the biosimilar candidate PF-582

Confluence Life Sciences discloses ITK kinase inhibitors

Actelion Pharmaceuticals develops CXCR3 receptor antagonists

Helsinn Group and MEI Pharma enter strategic agreement to develop pracinostat

Kissei and JCR initiate phase III clinical trial of the biosimilar agent JR-131

Vonvendi launched in the U.S. as the first and only recombinant von Willebrand factor treatment

Tafamidis demonstrates long-term benefits in transthyretin hereditary amyloid polyneuropathy

Ablynx reports topline phase IIb results for vobarilizumab in patients with rheumatoid arthritis

NIH awards a new contract to the IAVI to advance AIDS vaccine development

Mitsubishi Tanabe Pharma reports highlights of first quarter of fiscal 2016

Adverum and Editas collaborate on genome-editing medicines

Pluristem Therapeutics' critical limb ischemia program awarded USD 8 million

BMI1 shows promise as a target in lung cancer patients with loss of C/EBPalpha expression

Summit Therapeutics shows positive phase I results for new ezutromid formulation

Aldeyra Therapeutics reports positive results for NS-2 trial

Teijin and Versartis enter strategic alliance for development and commercialization of somavaratan

Celsion signs long-term agreement with Zhejiang Hisun Pharmaceutical for EGEN-001

Fevipiprant shows favorable efficacy and safety in persistent eosinophilic asthma

Biogen set to launch new standalone company named Bioverativ next year

Medical Research Council awards funding for development of new tests for bacterial infections

GRP45 shows promise as a therapeutic target for obesity

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...